Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

New Strategy Reinvigorates Exhausted T Cells to Fight Cancer

As cancer cells grow, they pump out metabolic byproducts such as lactic acid into the tumor microenvironment. Exhausted T cells -; which have lost their cancer-fighting oomph -; consume this lactic acid, which further saps their energy, according to new research from the University of Pittsburgh and UPMC Hillman Cancer Center.

11 Nov 2024

A New Understanding of Viral Infection

Scientists studying animal viruses with the potential to infect humans have discovered a critical protein that could facilitate the spread of a family of organisms known as arteriviruses.

1 Nov 2024

Monoclonal Antibody Market Set to Triple by 2033, Revolutionizing Disease Treatment

Recent advancements in monoclonal antibody engineering are reshaping disease treatment, focusing on safety, effectiveness, and addressing current medical needs.

28 Oct 2024

Monoclonal Antibody SC27 Shows Broad Effectiveness Against SARS-CoV-2 Variants

A monoclonal antibody appears effective at neutralizing the numerous variants of SARS-CoV-2, as well as related viruses in animals that could pose a threat if they were to begin spreading in people.

10 Sep 2024

New Biomarker Offers Early Detection of ALS and FTD

Two progressively degenerative diseases, amyotrophic lateral sclerosis (ALS, commonly known as Lou Gehrig's disease) and frontotemporal dementia (FTD, recently in the news with the diagnoses of actor Bruce Willis and talk show host Wendy Williams), are linked by more than the fact that they both damage nerve cells critical to normal functioning -; the former affecting nerves in the brain and spinal cord leading to loss of movement, the latter eroding the brain regions controlling personality, behavior and language.

19 Mar 2024

NIH Researchers Map Vulnerable Sites on Epstein-Barr Virus gp42 Protein

Studies of interactions between two lab-generated monoclonal antibodies (mAbs) and an essential Epstein-Barr virus (EBV) protein have uncovered targets that could be exploited in designing treatments and vaccines for this extremely common virus.

13 Mar 2024

Gene Splicing Affects CD20 Expression and Response to Cancer Immunotherapy

Immunotherapies that target the CD20 antigen have revolutionized how patients with a variety of blood cancers and hematologic disorders have been treated.

17 Nov 2023

New Insights Into Tumor-Immune Interactions Could Lead to More Effective Therapies for Multiple Myeloma

A multicenter study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine shows how interactions between tumor cells and immune components of the microenvironment can impact treatment responses and outcomes in patients newly diagnosed with multiple myeloma who undergo combination treatments that include targeted immunotherapy.

10 Nov 2023

New Insights Into How Cells Maintain Optimal Health

A group of researchers has unearthed the secrets behind a tiny but crucial protein that shuttles zinc ions (Zn2+) within our bodies. The discovery offers a deeper understanding of how our cells maintain optimal health.

4 Sep 2023

Targeting Respiratory Viral Infections with a New Immunotherapy Treatment

A researcher at the University of Central Florida College of Medicine has created a novel, more effective therapy for acute respiratory viral infections, a significant global cause of illness each year.

16 May 2023

Antibacterial Biologic Agent Effective Against Staphylococcus Aureus Infections in Early Tests

Researchers at NYU Grossman School of Medicine and Janssen Biotech, Inc. have shown in early tests that a bioengineered drug candidate can counter infection with Staphylococcus aureus – a bacterial species widely resistant to antibiotics and a major cause of death in hospitalized patients.

25 Apr 2023

Role of Engineered E. coli in Sending Therapeutic Nanobodies to the Gut

Numerous bacterium types have taken up residence in humans. Currently, research is concentrated on genetically modifying these bacteria to increase their inherent therapeutic qualities.

5 Apr 2023

Single monoclonal antibody infusion can strengthen the body's fight against yellow fever

New research from Oregon Health & Science University and collaborators indicates lab-made antibodies may be able to cure people infected with yellow fever, a virus for which there is no treatment.

30 Mar 2023

New class of oral drugs inhibits a diverse range of SARS-CoV-2 strains

The constant evolution of new COVID-19 variants makes it critical for clinicians to have multiple therapies in their arsenal for treating drug-resistant infections. Researchers have now discovered that a new class of oral drugs that acts directly on human cells can inhibit a diverse range of pathogenic SARS-CoV-2 strains.

13 Mar 2023

New model, C. elegans, helps pursue research on Parkinson's disease

A tiny worm called the C. elegans is enabling scientists to explore the emerging theory that Parkinson's disease starts in the gut.

1 Mar 2023

Herpesvirus infection boosts host cellular immunity: Study

A new editorial was published in Genes & Cancer on January 19th, 2023, entitled, "Severe herpesvirus infection beats adult T-cell leukemia/lymphoma."

27 Feb 2023

Prototype treatment shows great potential in neutralizing snake toxins from multiple species

Prototype treatment for snake bite envenoming proves effective against the venom of African and Asian elapid snakes, such as some cobra, mamba, and krait species, new research shows.

24 Feb 2023

Study shows how convalescent plasma can be used as effective treatment during future pandemics

Three years into the COVID-19 pandemic, new variant outbreaks continue to fuel economic disruptions and hospitalizations across the globe.

22 Feb 2023

Adding antioxidants to cell cultures for efficient production of antibodies

Researchers at the Department of Chemical Engineering, Indian Institute of Technology, India, have investigated the effects of oxidative stress on the production of monoclonal antibodies (mAbs), and how antioxidants can alleviate this stress to improve their performance.

16 Feb 2023

UC San Diego Alpha Clinic awarded $8 million to bring new stem cell-based therapies to patients

Stem cells show particular promise in treating diseases for which few other effective treatments exist.

25 Nov 2022